Shares of ZyVersa Therapeutics, Inc. (ZVSA) gained nearly 8% on Monday morning after the clinical stage specialty biopharmaceutical company announced that acclaimed inflammasome researchers from the University of Miami Miller School of Medicine and inventors of Inflammasome ASC Inhibitor IC 100, have published a scientific paper in the peer-reviewed journal, Frontiers in Molecular Neuroscience, highlighting how inflammasome-mediated inflammation in Alzheimer's disease can trigger inflammation in the heart.
ZVSA is currently trading at $5.28, up $0.39 or 7.98%, on the Nasdaq. The stock opened at $6.53 after closing Friday at $4.89. The stock has traded between $4.44 and $220.85 in the past 52-week period.
The paper titled, "Extracellular vesicles mediate inflammasome signaling in the brain and heart of Alzheimer's disease mice," summarizes research evaluating serum and tissue cultures from an AD mouse model, and experiments of adoptive transfer of EV from AD patients into cardiovascular cells.
For comments and feedback contact: editorial@rttnews.com
Business News